Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Semafore Pharmaceuticals Inc. has raised $9.5 million in equity partly to finance Phase I clinical tests of its cancer treatment.
The start-up Indianapolis drug developer said both existing and new investors were involved in the infusion, and that the funding would be paired with $4 million received last year from the state’s 21st Century Research and Technology Fund, the Cancer Treatment Research Foundation and the Multiple Myeloma Research Foundation.
Please enable JavaScript to view this content.
